Zobrazeno 1 - 10 of 27 pro vyhledávání: '"V, Secondo"'
2
Large granular lymphocyte leukemia associated with hepatocellular carcinoma: a case report
Autor: G, Borgonovo, V, Secondo, E, Varaldo, V, Pistoia, M, Gobbi, F P, Mattioli
Publikováno v: Haematologica. 81(2)
The association of large granular lymphocyte leukemia (LGL-L) with hepatocellular carcinoma in a 55-year-old patient is described. An increased number of LGL was seen on peripheral blood smears. The immunophenotype was CD3+, CD4-, CD8+, and a study o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6824bc82fca44af88c35152140e5ffab
https://pubmed.ncbi.nlm.nih.gov/8641651
Zobrazit plný text záznamu
3
Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients
Autor: L, Merlini, V, Secondo, S, Mammoliti, P, Bellotti, C, Castello, L, Gallo
Publikováno v: Anticancer research. 14(3B)
We have evaluated the efficacy and toxicity of a chemotherapy consisting of methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in 21 advanced breast cancer patients. Among 20 evaluable patients, objective response was obtained in 6 patients (3
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6e7d746cd726a07a084869ced4275366
https://pubmed.ncbi.nlm.nih.gov/8067717
Zobrazit plný text záznamu
4
Crossover study with cisplatin or carboplatin in advanced ovarian cancer
Autor: G. Donadio, S. Mammoliti, Riccardo Rosso, Pierfranco Conte, M. Bruzzone, L. Repetto, V. Secondo, T Guido, Nicola Ragni, S. Chiara, Franco Odicino
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination chemotherapy containing cisplatin or carboplatin were entered into a crossover study in which the analog not previously assigned was administered alone
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f1664af7e2b752ddcfa05b418fe4d9
http://hdl.handle.net/11379/465674
Zobrazit plný text záznamu
6
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial
Autor: G, Ambrosini, M, Balli, G, Garusi, R, Demicheli, A, Jirillo, G, Bonciarelli, G, Bruscagnin, G, Fila, C, Bumma, F, Lacroix, F, Buzzi, F, Di Costanzo, D, Padalino, M, Brugia, F, Calabresi, M, Natali, G, Cartei, G, Chiesa, B, Blasina, E, Ciambellotti, G, Moro, S, D'Aquino, G, Altavilla, V, Adamo, D, De Maria, A M, Falchi, P, Bertoncelli, A, Farris, M, Fiorentino, A, Fornasiero, V, Fosser, O, Daniele, C M, Foggi, G B, Speranza, S, Sartori, E, Camilluzzi, L, Gallo, R, Poggio, V, Secondo, A, Gambi, F, Grignani, E, Capodicasa, M, Lopez, P, Papaldo, L, Di Lauro, P, Vici, G, Marenco, U, Folco, F, Bonanni, P, Marsilio, G, Palazzotto, A, Di Carlo, M P, Cusimano, G, Pastorino, C, Puccetti, M, Giusto, L, Rausa, N, Gebbia, S, Palmeri, N, D'Alessandro, F, Saccani, G, Becchi, G, Schieppati, I, Spinelli, A, Tagliagambe, M, Tonato, V, Minotti, A, Ardia, D, Viaro, P, De Micheli, G, Zingali, G, Sacchetti, C, Intini
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 6(6)
From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated to receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::07bad104285563cf7a05b3ea5396011d
https://pubmed.ncbi.nlm.nih.gov/2897433
Zobrazit plný text záznamu
7
Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer
Autor: Paolo Bruzzi, C. Moroni, C. Viscoti, A. Terragna, A. Comelli, V. Secondo, L. Boni, A. Fabbri, G. Dini
Publikováno v: Scopus-Elsevier
Two antibiotic regimens, ceftazidime plus amikacin and ceftazidime plus vancomycin, were compared in a prospective, randomized clinical trial as empiric therapy in febrile granulocytopenic children with cancer. The rate of response was similar in the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7353625a3f6824008b33bfb52c56a276
http://www.scopus.com/inward/record.url?eid=2-s2.0-0025735673&partnerID=MN8TOARS
Zobrazit plný text záznamu
8
P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL)
Autor: A. Levis, Paolo Gavarotti, Giuseppe Todeschini, V. Secondo, Luigi Resegotti, C. Volta, Roberto Freilone, Massimo Pini, D. Rota Scalabrini, Lorella Orsucci, Flavia Salvi, Marilena Bertini, Ester Orlandi, Umberto Vitolo, Barbara Botto, Michele Pizzuti, Piera Viero
Publikováno v: Europe PubMed Central
Scopus-Elsevier
Summary Background Chemotherapy regimens devised for elderly patients with intermediate-high grade NHL are a matter of discussion. The aim is to reduce general toxicity without loosing an antilymphoma effect. The most important limiting factor of che
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58af601a4480fd0aa0e1607c40112e44
http://europepmc.org/abstract/med/7535080
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje